Management of Rising PSA After Cryoablation
Introduction to Management
- The National Comprehensive Cancer Network recommends that for a male with rising PSA after cryoablation, observation without Lupron is the most appropriate approach given his limited life expectancy, unless he has symptomatic disease or documented metastases 1
Rationale for Approach
- Men with life expectancy less than 10 years should undergo active surveillance rather than aggressive treatment, as 5- to 10-year cancer-specific mortality is very low for most prostate cancers 1
- At age 91, the median life expectancy is approximately 4-5 years, making the likelihood of dying from prostate cancer extremely low compared to competing causes of mortality 1
- ADT as primary treatment for localized prostate cancer does not improve survival and is not recommended 1
Considerations for ADT
- Lupron should only be initiated if specific high-risk features are present, such as documented metastatic disease on imaging (bone scan, CT, or PSMA PET/CT) 2, 3
- Extremely rapid PSA doubling time (less than 3 months) suggesting aggressive biology 3
- PSA velocity showing more than tripling in one year 3
Alternative Therapies
- Salvage radiation therapy (SRT) after cryoablation failure may offer disease control without the systemic toxicity of ADT 4, 5
- The addition of short-term ADT to SRT may improve progression-free survival in select cases, but this must be balanced against toxicity in a 91-year-old 5